Targeting the tumor microenvironment in pancreatic ductal adenocarcinoma

References

• Conroy T, Desseigne F, Ychou M, et al. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med. 2011;364(19):1817–1825.
   PubMed Web of Science ®Google Scholar
• Von Hoff DD, Ervin T, Arena FP, et al. Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. N Engl J Med. 2013;369(18):1691–1703.
   PubMed Web of Science ®Google Scholar
• Tahara J, Shimizu K, Otsuka N, et al. Gemcitabine plus nab-paclitaxel vs. FOLFIRINOX for patients with advanced pancreatic cancer. Cancer Chemother Pharmacol. 2018;82(2):245–250.
   PubMed Web of Science ®Google Scholar
• Neesse A, Michl P, Frese KK, et al. Stromal biology and therapy in pancreatic cancer. Gut. 2011;60(6):861–868.
   PubMed Web of Science ®Google Scholar
• Dauer P, Nomura A, Saluja A, et al. Microenvironment in determining chemo-resistance in pancreatic cancer: neighborhood matters. Pancreatology. 2017;17(1):7–12.
   PubMed Web of Science ®Google Scholar
• Lindsey S, Langhans SA. Crosstalk of oncogenic signaling pathways during epithelial-mesenchymal transition. Front Oncol. 2014;4:358.
   PubMedGoogle Scholar
• Bynigeri RR, Jakkampudi A, Jangala R, et al. Pancreatic stellate cell: pandora’s box for pancreatic disease biology. World J Gastroenterol. 2017;23(3):382–405.
   PubMed Web of Science ®Google Scholar
• Asahina K, Tsai SY, Li P, et al. Mesenchymal origin of hepatic stellate cells, submesothelial cells, and perivascular mesenchymal cells during mouse liver development. Hepatology. 2009;49(3):998–1011.
   PubMed Web of Science ®Google Scholar
• Marrache F, Pendyala S, Bhagat G, et al. Role of bone marrow-derived cells in experimental chronic pancreatitis. Gut. 2008;57(8):1113–1120.
   PubMed Web of Science ®Google Scholar
• Scarlett CJ, Colvin EK, Pinese M, et al. Recruitment and activation of pancreatic stellate cells from the bone marrow in pancreatic cancer: a model of tumor-host interaction. PLoS One. 2011;6(10):e26088.
   PubMed Web of Science ®Google Scholar
• Ino K, Masuya M, Tawara I, et al. Monocytes infiltrate the pancreas via the MCP-1/CCR2 pathway and differentiate into stellate cells. PLoS One. 2014;9(1):e84889.
   PubMed Web of Science ®Google Scholar
• Riopel MM, Li J, Liu S, et al. beta1 integrin-extracellular matrix interactions are essential for maintaining exocrine pancreas architecture and function. Lab Invest. 2013;93(1):31–40.
   PubMed Web of Science ®Google Scholar
• Ferdek PE, Jakubowska MA. Biology of pancreatic stellate cells-more than just pancreatic cancer. Pflugers Arch. 2017;469(9):1039–1050.
   PubMed Web of Science ®Google Scholar
• Phillips PA, McCarroll JA, Park S, et al. Rat pancreatic stellate cells secrete matrix metalloproteinases: implications for extracellular matrix turnover. Gut. 2003;52(2):275–282.
   PubMed Web of Science ®Google Scholar
• Bachem MG, Schneider E, Gross H, et al. Identification, culture, and characterization of pancreatic stellate cells in rats and humans. Gastroenterology. 1998;115(2):421–432.
   PubMed Web of Science ®Google Scholar
• Mews P, Phillips P, Fahmy R, et al. Pancreatic stellate cells respond to inflammatory cytokines: potential role in chronic pancreatitis. Gut. 2002;50(4):535–541.
   PubMed Web of Science ®Google Scholar
• Tahara H, Sato K, Yamazaki Y, et al. Transforming growth factor-alpha activates pancreatic stellate cells and may be involved in matrix metalloproteinase-1 upregulation. Lab Invest. 2013;93(6):720–732.
   PubMed Web of Science ®Google Scholar
• Apte MV, Haber PS, Darby SJ, et al. Pancreatic stellate cells are activated by proinflammatory cytokines: implications for pancreatic fibrogenesis. Gut. 1999;44(4):534–541.
   PubMed Web of Science ®Google Scholar
• Vogelmann R, Ruf D, Wagner M, et al. Effects of fibrogenic mediators on the development of pancreatic fibrosis in a TGF-beta1 transgenic mouse model. Am J Physiol Gastrointest Liver Physiol. 2001;280(1):G164–172.
   PubMed Web of Science ®Google Scholar
• Masamune A, Shimosegawa T. Signal transduction in pancreatic stellate cells. J Gastroenterol. 2009;44(4):249–260.
   PubMed Web of Science ®Google Scholar
• Bachem MG, Schunemann M, Ramadani M, et al. Pancreatic carcinoma cells induce fibrosis by stimulating proliferation and matrix synthesis of stellate cells. Gastroenterology. 2005;128(4):907–921.
   PubMed Web of Science ®Google Scholar
• Schneider E, Schmid-Kotsas A, Zhao J, et al. Identification of mediators stimulating proliferation and matrix synthesis of rat pancreatic stellate cells. Am J Physiol Cell Physiol. 2001;281(2):C532–543.
   PubMed Web of Science ®Google Scholar
• Andoh A, Takaya H, Saotome T, et al. Cytokine regulation of chemokine (IL-8, MCP-1, and RANTES) gene expression in human pancreatic periacinar myofibroblasts. Gastroenterology. 2000;119(1):211–219.
   PubMed Web of Science ®Google Scholar
• Kalluri R. The biology and function of fibroblasts in cancer. Nat Rev Cancer. 2016;16(9):582–598.
   PubMed Web of Science ®Google Scholar
• Nielsen MFB, Mortensen MB, Detlefsen S. Typing of pancreatic cancer-associated fibroblasts identifies different subpopulations. World J Gastroenterol. 2018;24(41):4663–4678.
   PubMed Web of Science ®Google Scholar
• Neuzillet C, Tijeras-Raballand A, Ragulan C, et al. Inter- and intra-tumoral heterogeneity in cancer-associated fibroblasts of human pancreatic ductal adenocarcinoma. J Pathol. 2019;248(1):51-65.
   Google Scholar
• Hwang RF, Moore T, Arumugam T, et al. Cancer-associated stromal fibroblasts promote pancreatic tumor progression. Cancer Res. 2008;68(3):918–926.
   PubMed Web of Science ®Google Scholar
• Cavaco ACM, Rezaei M, Caliandro MF, et al. The interaction between laminin-332 and alpha3beta1 integrin determines differentiation and maintenance of CAFs, and supports invasion of pancreatic duct adenocarcinoma cells. Cancers (Basel). 2019;11(1):1-20.
   Google Scholar
• Cho H, Seo Y, Loke KM, et al. Cancer-stimulated cafs enhance monocyte differentiation and protumoral TAM activation via IL6 and GM-CSF Secretion. Clin Cancer Res. 2018;24(21):5407–5421.
   PubMed Web of Science ®Google Scholar
• Porembka MR, Mitchem JB, Belt BA, et al. Pancreatic adenocarcinoma induces bone marrow mobilization of myeloid-derived suppressor cells which promote primary tumor growth. Cancer Immunol Immunother. 2012;61(9):1373–1385.
   PubMed Web of Science ®Google Scholar
• Diaz-Montero CM, Salem ML, Nishimura MI, et al. Increased circulating myeloid-derived suppressor cells correlate with clinical cancer stage, metastatic tumor burden, and doxorubicin-cyclophosphamide chemotherapy. Cancer Immunol Immunother. 2009;58(1):49–59.
   PubMed Web of Science ®Google Scholar
• Liu G, Bi Y, Shen B, et al. SIRT1 limits the function and fate of myeloid-derived suppressor cells in tumors by orchestrating HIF-1alpha-dependent glycolysis. Cancer Res. 2014;74(3):727–737.
   PubMed Web of Science ®Google Scholar
• Corzo CA, Cotter MJ, Cheng P, et al. Mechanism regulating reactive oxygen species in tumor-induced myeloid-derived suppressor cells. J Immunol. 2009;182(9):5693–5701.
   PubMed Web of Science ®Google Scholar
• Otsuji M, Kimura Y, Aoe T, et al. Oxidative stress by tumor-derived macrophages suppresses the expression of CD3 zeta chain of T-cell receptor complex and antigen-specific T-cell responses. Proc Natl Acad Sci U S A. 1996;93(23):13119–13124.
   PubMed Web of Science ®Google Scholar
• Pinton L, Solito S, Damuzzo V, et al. Activated T cells sustain myeloid-derived suppressor cell-mediated immune suppression. Oncotarget. 2016;7(2):1168–1184.
   PubMedGoogle Scholar
• Kumar V, Cheng P, Condamine T, et al. CD45 Phosphatase inhibits STAT3 transcription factor activity in myeloid cells and promotes tumor-associated macrophage differentiation. Immunity. 2016;44(2):303–315.
   PubMed Web of Science ®Google Scholar
• Zhu Y, Herndon JM, Sojka DK, et al. Tissue-Resident macrophages in pancreatic ductal adenocarcinoma originate from embryonic hematopoiesis and promote tumor progression. Immunity. 2017;47(2):323–338 e326.
   PubMed Web of Science ®Google Scholar
• Habtezion A, Edderkaoui M, Pandol SJ. Macrophages and pancreatic ductal adenocarcinoma. Cancer Lett. 2016;381(1):211–216.
   PubMed Web of Science ®Google Scholar
• Liou GY, Doppler H, Necela B, et al. Mutant KRAS-induced expression of ICAM-1 in pancreatic acinar cells causes attraction of macrophages to expedite the formation of precancerous lesions. Cancer Discov. 2015;5(1):52–63.
   PubMed Web of Science ®Google Scholar
• Ruffell B, Affara NI, Coussens LM. Differential macrophage programming in the tumor microenvironment. Trends Immunol. 2012;33(3):119–126.
   PubMed Web of Science ®Google Scholar
• Liou GY, Bastea L, Fleming A, et al. The presence of interleukin-13 at pancreatic ADM/PanIN lesions alters macrophage populations and mediates pancreatic tumorigenesis. Cell Rep. 2017;19(7):1322–1333.
   PubMed Web of Science ®Google Scholar
• Kurahara H, Shinchi H, Mataki Y, et al. Significance of M2-polarized tumor-associated macrophage in pancreatic cancer. J Surg Res. 2011;167(2):e211–219.
   PubMed Web of Science ®Google Scholar
• Chen SJ, Zhang QB, Zeng LJ, et al. Distribution and clinical significance of tumour-associated macrophages in pancreatic ductal adenocarcinoma: a retrospective analysis in China. Curr Oncol. 2015;22(1):e11–19.
   PubMed Web of Science ®Google Scholar
• Ben-Baruch A. Inflammation-associated immune suppression in cancer: the roles played by cytokines, chemokines and additional mediators. Semin Cancer Biol. 2006;16(1):38–52.
   PubMed Web of Science ®Google Scholar
• Bastea LI, Liou GY, Pandey V, et al. Pomalidomide alters pancreatic macrophage populations to generate an immune-responsive environment at precancerous and cancerous lesions. Cancer Res. 2019;
   PubMed Web of Science ®Google Scholar
• Zhang H, Liu C, Kong Y, et al. TGFbeta signaling in pancreatic ductal adenocarcinoma. Tumour Biol. 2015;36(3):1613–1618.
   PubMedGoogle Scholar
• Meng F, Li C, Li W, et al. Interaction between pancreatic cancer cells and tumor-associated macrophages promotes the invasion of pancreatic cancer cells and the differentiation and migration of macrophages. IUBMB Life. 2014;66(12):835–846.
   PubMed Web of Science ®Google Scholar
• Karnevi E, Andersson R, Rosendahl AH. Tumour-educated macrophages display a mixed polarisation and enhance pancreatic cancer cell invasion. Immunol Cell Biol. 2014;92(6):543–552.
   PubMed Web of Science ®Google Scholar
• Condeelis J, Pollard JW. Macrophages: obligate partners for tumor cell migration, invasion, and metastasis. Cell. 2006;124(2):263–266.
   PubMed Web of Science ®Google Scholar
• Coffelt SB, Hughes R, Lewis CE. Tumor-associated macrophages: effectors of angiogenesis and tumor progression. Biochim Biophys Acta. 2009;1796(1):11–18.
   PubMed Web of Science ®Google Scholar
• Joyce JA, Pollard JW. Microenvironmental regulation of metastasis. Nat Rev Cancer. 2009;9(4):239–252.
   PubMed Web of Science ®Google Scholar
• Raul Casso GM Role of tumor associated macrophages in regulating pancreatic cancer progression. World J Immunol. 2016;6(1):9-18.
   Google Scholar
• Ozdemir BC, Pentcheva-Hoang T, Carstens JL, et al. Depletion of carcinoma-associated fibroblasts and fibrosis induces immunosuppression and accelerates pancreas cancer with reduced survival. Cancer Cell. 2014;25(6):719–734.
   PubMed Web of Science ®Google Scholar
• Elahi-Gedwillo KY, Carlson M, Zettervall J, et al. Antifibrotic therapy disrupts stromal barriers and modulates the immune landscape in pancreatic ductal adenocarcinoma. Cancer Res. 2019;79(2):372–386.
   PubMed Web of Science ®Google Scholar
• Han S, Latchoumanin O, Wu G, et al. Recent clinical trials utilizing chimeric antigen receptor T cells therapies against solid tumors. Cancer Lett. 2017;390:188–200.
   PubMed Web of Science ®Google Scholar
• Einama T, Kamachi H, Nishihara H, et al. Co-expression of mesothelin and CA125 correlates with unfavorable patient outcome in pancreatic ductal adenocarcinoma. Pancreas. 2011;40(8):1276–1282.
   PubMed Web of Science ®Google Scholar
• Beatty GL, Haas AR, Maus MV, et al. Mesothelin-specific chimeric antigen receptor mRNA-engineered T cells induce anti-tumor activity in solid malignancies. Cancer Immunol Res. 2014;2(2):112–120.
   PubMed Web of Science ®Google Scholar
• Beatty GL, O’Hara MH, Lacey SF, et al. activity of mesothelin-specific chimeric antigen receptor T cells against pancreatic carcinoma metastases in a phase 1 trial. Gastroenterology. 2018;155(1):29–32.
   PubMed Web of Science ®Google Scholar
• Akce M, Zaidi MY, Waller EK, et al. The potential of CAR T cell therapy in pancreatic cancer. Front Immunol. 2018;9:2166.
   PubMed Web of Science ®Google Scholar
• Aglietta M, Barone C, Sawyer MB, et al. A phase I dose escalation trial of tremelimumab (CP-675,206) in combination with gemcitabine in chemotherapy-naive patients with metastatic pancreatic cancer. Ann Oncol. 2014;25(9):1750–1755.
   PubMed Web of Science ®Google Scholar
• Lu C, Paschall AV, Shi H, et al. The MLL1-H3K4me3 Axis-Mediated PD-L1 expression and pancreatic cancer immune evasion. J Natl Cancer Inst. 2017;109(6):1-12.
   Google Scholar
• Lutz ER, Wu AA, Bigelow E, et al. Immunotherapy converts nonimmunogenic pancreatic tumors into immunogenic foci of immune regulation. Cancer Immunol Res. 2014;2(7):616–631.
   PubMed Web of Science ®Google Scholar
• Le DT, Lutz E, Uram JN, et al. Evaluation of ipilimumab in combination with allogeneic pancreatic tumor cells transfected with a GM-CSF gene in previously treated pancreatic cancer. J Immunother. 2013;36(7):382–389.
   PubMed Web of Science ®Google Scholar
• Jiang H, Hegde S, Knolhoff BL, et al. Targeting focal adhesion kinase renders pancreatic cancers responsive to checkpoint immunotherapy. Nat Med. 2016;22(8):851–860.
   PubMed Web of Science ®Google Scholar
• Beatty GL, Li Y, Long KB. Cancer immunotherapy: activating innate and adaptive immunity through CD40 agonists. Expert Rev Anticancer Ther. 2017;17(2):175–186.
   PubMed Web of Science ®Google Scholar
• Vonderheide RH, Bajor DL, Winograd R, et al. CD40 immunotherapy for pancreatic cancer. Cancer Immunol Immunother. 2013;62(5):949–954.
   PubMed Web of Science ®Google Scholar
• Mach F, Schonbeck U, Sukhova GK, et al. Functional CD40 ligand is expressed on human vascular endothelial cells, smooth muscle cells, and macrophages: implications for CD40-CD40 ligand signaling in atherosclerosis. Proc Natl Acad Sci U S A. 1997;94(5):1931–1936.
   PubMed Web of Science ®Google Scholar
• Schoenberger SP, Toes RE, van der Voort EI, et al. T-cell help for cytotoxic T lymphocytes is mediated by CD40-CD40L interactions. Nature. 1998;393(6684):480–483.
   PubMed Web of Science ®Google Scholar
• Byrne KT, Vonderheide RH. CD40 stimulation obviates innate sensors and drives T cell immunity in cancer. Cell Rep. 2016;15(12):2719–2732.
   PubMed Web of Science ®Google Scholar
• Ebert PJR, Cheung J, Yang Y, et al. MAP kinase inhibition promotes T cell and anti-tumor activity in combination with PD-L1 checkpoint blockade. Immunity. 2016;44(3):609–621.
   PubMed Web of Science ®Google Scholar
• Azenshtein E, Luboshits G, Shina S, et al. The CC chemokine RANTES in breast carcinoma progression: regulation of expression and potential mechanisms of promalignant activity. Cancer Res. 2002;62(4):1093–1102.
   PubMed Web of Science ®Google Scholar
• Monti P, Leone BE, Marchesi F, et al. The CC chemokine MCP-1/CCL2 in pancreatic cancer progression: regulation of expression and potential mechanisms of antimalignant activity. Cancer Res. 2003;63(21):7451–7461.
   PubMed Web of Science ®Google Scholar
• Linde N, Lederle W, Depner S, et al. Vascular endothelial growth factor-induced skin carcinogenesis depends on recruitment and alternative activation of macrophages. J Pathol. 2012;227(1):17–28.
   PubMed Web of Science ®Google Scholar
• Uutela M, Wirzenius M, Paavonen K, et al. PDGF-D induces macrophage recruitment, increased interstitial pressure, and blood vessel maturation during angiogenesis. Blood. 2004;104(10):3198–3204.
   PubMed Web of Science ®Google Scholar
• Hu H, Hang JJ, Han T, et al. The M2 phenotype of tumor-associated macrophages in the stroma confers a poor prognosis in pancreatic cancer. Tumour Biol. 2016;37(7):8657–8664.
   PubMedGoogle Scholar
• Hagemann T, Lawrence T, McNeish I, et al. “Re-educating” tumor-associated macrophages by targeting NF-kappaB. J Exp Med. 2008;205(6):1261–1268.
   PubMed Web of Science ®Google Scholar
• Kratochvill F, Neale G, Haverkamp JM, et al. TNF counterbalances the emergence of M2 tumor macrophages. Cell Rep. 2015;12(11):1902–1914.
   PubMed Web of Science ®Google Scholar
• Cui R, Yue W, Lattime EC, et al. Targeting tumor-associated macrophages to combat pancreatic cancer. Oncotarget. 2016;7(31):50735–50754.
   PubMedGoogle Scholar
• Jaiswal S, Chao MP, Majeti R, et al. Macrophages as mediators of tumor immunosurveillance. Trends Immunol. 2010;31(6):212–219.
   PubMed Web of Science ®Google Scholar
• Nagaraj S, Youn JI, Weber H, et al. Anti-inflammatory triterpenoid blocks immune suppressive function of MDSCs and improves immune response in cancer. Clin Cancer Res. 2010;16(6):1812–1823.
   PubMed Web of Science ®Google Scholar
• Zhu Y, Knolhoff BL, Meyer MA, et al. CSF1/CSF1R blockade reprograms tumor-infiltrating macrophages and improves response to T-cell checkpoint immunotherapy in pancreatic cancer models. Cancer Res. 2014;74(18):5057–5069.
   PubMed Web of Science ®Google Scholar
• Bunt SK, Mohr AM, Bailey JM, et al. Rosiglitazone and gemcitabine in combination reduces immune suppression and modulates T cell populations in pancreatic cancer. Cancer Immunol Immunother. 2013;62(2):225–236.
   PubMed Web of Science ®Google Scholar
• Huang HL, Chao MW, Chen CC, et al. LTP-1, a novel antimitotic agent and Stat3 inhibitor, inhibits human pancreatic carcinomas in vitro and in vivo. Sci Rep. 2016;6:27794.
   PubMed Web of Science ®Google Scholar
• Tai LH, Alkayyal AA, Leslie AL, et al. Phosphodiesterase-5 inhibition reduces postoperative metastatic disease by targeting surgery-induced myeloid derived suppressor cell-dependent inhibition of natural killer cell cytotoxicity. Oncoimmunology. 2018;7(6):e1431082.
   PubMed Web of Science ®Google Scholar
• Rodriguez PC, Hernandez CP, Quiceno D, et al. Arginase I in myeloid suppressor cells is induced by COX-2 in lung carcinoma. J Exp Med. 2005;202(7):931–939.
   PubMed Web of Science ®Google Scholar
• Suzuki E, Kapoor V, Jassar AS, et al. Gemcitabine selectively eliminates splenic Gr-1+/CD11b+ myeloid suppressor cells in tumor-bearing animals and enhances antitumor immune activity. Clin Cancer Res. 2005;11(18):6713–6721.
   PubMed Web of Science ®Google Scholar
• Gurlevik E, Fleischmann-Mundt B, Brooks J, et al. Administration of gemcitabine after pancreatic tumor resection in mice induces an antitumor immune response mediated by natural killer cells. Gastroenterology. 2016;151(2):338–350 e337.
   PubMed Web of Science ®Google Scholar
• Weniger M, Honselmann KC, Liss AS. The extracellular matrix and pancreatic cancer: A complex relationship. Cancers (Basel). 2018;10(9):316.
   Web of Science ®Google Scholar
• Topalovski M, Brekken RA. Matrix control of pancreatic cancer: new insights into fibronectin signaling. Cancer Lett. 2016;381(1):252–258.
   PubMed Web of Science ®Google Scholar
• Knapinska AM, Estrada CA, Fields GB. The roles of matrix metalloproteinases in pancreatic cancer. Prog Mol Biol Transl Sci. 2017;148:339–354.
   PubMed Web of Science ®Google Scholar
• Bramhall SR, Schulz J, Nemunaitis J, et al. A double-blind placebo-controlled, randomised study comparing gemcitabine and marimastat with gemcitabine and placebo as first line therapy in patients with advanced pancreatic cancer. Br J Cancer. 2002;87(2):161–167.
   PubMed Web of Science ®Google Scholar
• Zhang K, Chen D, Jiao X, et al. Slug enhances invasion ability of pancreatic cancer cells through upregulation of matrix metalloproteinase-9 and actin cytoskeleton remodeling. Lab Invest. 2011;91(3):426–438.
   PubMed Web of Science ®Google Scholar
• Moore MJ, Hamm J, Dancey J, et al. Comparison of gemcitabine versus the matrix metalloproteinase inhibitor BAY 12-9566 in patients with advanced or metastatic adenocarcinoma of the pancreas: a phase III trial of the national cancer institute of canada clinical trials group. J Clin Oncol. 2003;21(17):3296–3302.
   PubMed Web of Science ®Google Scholar
• Li L, Li H. Role of microRNA-mediated MMP regulation in the treatment and diagnosis of malignant tumors. Cancer Biol Ther. 2013;14(9):796–805.
   PubMed Web of Science ®Google Scholar
• Coons LB, L’Amoreaux WJ, Rosell-Davis R, et al. Fine structure of the fat body and nephrocytes in the life-stages of Dermacentor variabilis. Exp Appl Acarol. 1990;8(1–2):125–142.
   PubMedGoogle Scholar
• Giovannetti E, Funel N, Peters GJ, et al. MicroRNA-21 in pancreatic cancer: correlation with clinical outcome and pharmacologic aspects underlying its role in the modulation of gemcitabine activity. Cancer Res. 2010;70(11):4528–4538.
   PubMed Web of Science ®Google Scholar
• Xu Q, Li P, Chen X, et al. miR-221/222 induces pancreatic cancer progression through the regulation of matrix metalloproteinases. Oncotarget. 2015;6(16):14153–14164.
   PubMedGoogle Scholar
• Toole BP, Slomiany MG. Hyaluronan: a constitutive regulator of chemoresistance and malignancy in cancer cells. Semin Cancer Biol. 2008;18(4):244–250.
   PubMed Web of Science ®Google Scholar
• Provenzano PP, Cuevas C, Chang AE, et al. Enzymatic targeting of the stroma ablates physical barriers to treatment of pancreatic ductal adenocarcinoma. Cancer Cell. 2012;21(3):418–429.
   PubMed Web of Science ®Google Scholar
• Jacobetz MA, Chan DS, Neesse A, et al. Hyaluronan impairs vascular function and drug delivery in a mouse model of pancreatic cancer. Gut. 2013;62(1):112–120.
   PubMed Web of Science ®Google Scholar
• Thompson CB, Shepard HM, O’Connor PM, et al. Enzymatic depletion of tumor hyaluronan induces antitumor responses in preclinical animal models. Mol Cancer Ther. 2010;9(11):3052–3064.
   PubMed Web of Science ®Google Scholar
• Baumgartner G, Gomar-Hoss C, Sakr L, et al. The impact of extracellular matrix on the chemoresistance of solid tumors–experimental and clinical results of hyaluronidase as additive to cytostatic chemotherapy. Cancer Lett. 1998;131(1):85–99.
   PubMed Web of Science ®Google Scholar
• Hingorani SR, Harris WP, Beck JT, et al. Phase Ib study of PEGylated recombinant human hyaluronidase and gemcitabine in patients with advanced pancreatic cancer. Clin Cancer Res. 2016;22(12):2848–2854.
   PubMed Web of Science ®Google Scholar
• Balachandran VP, Beatty GL, Dougan SK. Broadening the impact of immunotherapy to pancreatic cancer: Challenges and opportunities. Gastroenterology. 2019;156:2056-2072.
   Web of Science ®Google Scholar
• Feng M, Chen JY, Weissman-Tsukamoto R, et al. Macrophages eat cancer cells using their own calreticulin as a guide: roles of TLR and Btk. Proc Natl Acad Sci U S A. 2015;112(7):2145–2150.
   PubMed Web of Science ®Google Scholar